rucaparib

Rucaparib (PF-01367338) is a PARP protein inhibitor (PARP-1 Ki=1.4 nM) and hexose hexose-6-phosphate dehydrogenase (H6PD) inhibitor with oral activity. Rucaparib exhibits antitumor activity, with activity against desmoplasia-resistant prostate cancer (CRPC).

Rucaparib Phosphate (PF-01367338 phosphate) is an inhibitor of PARP (Ki: 1.4 nM for PARP1) that is used in clinical therapy to sensitize cancer cells to chemotherapy.

Rucaparib monocamsylate (Rucaparib Camsylate) is a PARP inhibitor (PARP1,Ki of 1.4 nM). Rucaparib Camsylate also displays binding affinity to eight other PARP domains.

Rucaparib hydrochloride, also known as AG014699, is a powerful and orally active compound that inhibits PARP proteins including PARP-1, PARP-2, and PARP-3 with a Ki value of 1.4 nM for PARP1. Additionally, Rucaparib hydrochloride acts as a modest inhibitor of hexose-6-phosphate dehydrogenase (H6PD). This compound shows potential in research for castration-resistant prostate cancer (CRPC) [1] [2] [3] [4].

Rucaparib (AG014699) acetate is a highly effective oral inhibitor of PARP proteins, specifically targeting PARP-1, PARP-2, and PARP-3, with a Ki value of 1.4 nM for PARP1. Additionally, it exhibits inhibitory action on hexose-6-phosphate dehydrogenase (H6PD) to a moderate extent. Rucaparib acetate shows promise in the field of research for castration-resistant prostate cancer (CRPC). [1] [2] [3] [4]

Rucaparib (AG014699) tartrate is an orally active inhibitor of PARP proteins (PARP-1, PARP-2, and PARP-3) and acts on PARP-1 (Ki: 1.4 nM). It is also a hexose hexaphosphate dehydrogenase (H6PD) inhibitor and has potential for use in the study of destructive resistant prostate cancer (CRPC).

Rucaparib (AG014699) camsylate is an orally active inhibitor of PARP proteins (PARP-1, PARP-2, and PARP-3) with a Ki=1.4 nM for PARP-1, and also inhibits hexose hexaphosphate dehydrogenase (H6PD). Rucaparib camsylate has potential for investigation in debulking resistant prostate cancer (CRPC) studies.

Rucaparib-[13C,D3] (Standard) is a reference standard of Rucaparib-[13C,D3] intended for quantitative analysis, quality control, and related biochemical research applications.

iRucaparib-AP6, a non-trapping PARP1 degrader, blocks both the catalytic activity and scaffolding effects of PARP1. iRucaparib-AP6 is a highly efficient and specific PARP1 degrader based on Rucaparib by using the PROTAC approach.

Pomalidomide 4'-PEG3-azide is a chemically synthesized E3 ligase ligand-linker conjugate that incorporates the cereblon ligand derived from Pomalidomide, along with a linker. This compound is utilized in the synthesis of iRucaparib-TP3 (Compound 3), an effective PARP1 degrader developed through the PROTAC strategy and derived from Rucaparib.